-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated by Analysts at StockNews.com
Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated by Analysts at StockNews.com
Equities researchers at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Acorda Therapeutics Stock Down 13.3 %
ACOR stock opened at $0.29 on Monday. The company has a market cap of $6.95 million, a price-to-earnings ratio of -0.03 and a beta of 0.45. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 2.10. Acorda Therapeutics has a 12 month low of $0.28 and a 12 month high of $4.99. The firm has a 50-day moving average of $0.42 and a two-hundred day moving average of $0.79.
Get Acorda Therapeutics alerts:Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). The business had revenue of $31.05 million during the quarter. Acorda Therapeutics had a negative net margin of 98.25% and a negative return on equity of 90.29%.
Hedge Funds Weigh In On Acorda Therapeutics
Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC boosted its position in Acorda Therapeutics by 661.2% in the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock valued at $145,000 after buying an additional 270,588 shares during the period. Renaissance Technologies LLC boosted its position in Acorda Therapeutics by 27.4% in the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the period. Virtu Financial LLC purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $68,000. Finally, Prudential Financial Inc. purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 50.24% of the company's stock.About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Equities researchers at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
周一，StockNews.com的股票研究人员在向客户和投资者发布的一份研究报告中开始报道阿科达治疗公司(纳斯达克：ACOR-GET Rating)的股票。该经纪公司对这家生物制药公司的股票设定了“持有”评级。
Acorda Therapeutics Stock Down 13.3 %
Acorda治疗公司股价下跌13.3%
ACOR stock opened at $0.29 on Monday. The company has a market cap of $6.95 million, a price-to-earnings ratio of -0.03 and a beta of 0.45. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 2.10. Acorda Therapeutics has a 12 month low of $0.28 and a 12 month high of $4.99. The firm has a 50-day moving average of $0.42 and a two-hundred day moving average of $0.79.
雅高股价周一开盘报0.29美元。该公司市值为695万美元，市盈率为-0.03倍，贝塔系数为0.45。该公司的流动比率为1.86，速动比率为1.49，债务权益比率为2.10。Acorda Treeutics的12个月低点为0.28美元，12个月高位为4.99美元。该公司的50日移动均线切入位在0.42美元，200日移动均线切入位在0.79美元。
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). The business had revenue of $31.05 million during the quarter. Acorda Therapeutics had a negative net margin of 98.25% and a negative return on equity of 90.29%.
阿科达治疗公司(纳斯达克：ACOR-GET评级)最近一次发布季度收益数据是在8月4日星期四。这家生物制药公司公布了该季度每股收益(2.78美元)，低于分析师普遍预期的(0.36美元)至(2.42美元)。该业务在本季度的收入为3105万美元。Acorda Treeutics的净利润率为负98.25%，股本回报率为负90.29%。
Hedge Funds Weigh In On Acorda Therapeutics
对冲基金入股Acorda Treeutics
About Acorda Therapeutics
关于阿科达治疗公司
(Get Rating)
(获取评级)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治疗公司是一家生物制药公司，在美国开发和销售神经疾病的治疗方法。该公司在欧洲营销Ampyra(达法普利定)，一种改善多发性硬化症(MS)患者行走能力的口服药物；以及Inbrija，用于治疗帕金森病的间歇期。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- 免费获取StockNews.com关于Acorda治疗公司(ACOR)的研究报告
- 卡特彼勒能否在下跌的市场中走得更高？
- Dave&Buster‘s能免受高通胀和低支出的影响吗？
- 这三只表现最好的中型股应该出现在你的观察名单上吗？
- 华尔街对Datadog的热情会带来巨大的收益吗？
- MarketBeat：回顾一周9/19-9/23
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Acorda治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acorda Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧